Cargando…
The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy
BACKGROUND: The Allergic Rhinitis Clinical Management Pathway (AR-CMaP) was developed to overcome the challenge of implementing current AR guidelines in the Australian community pharmacy practice and support pharmacists in optimally managing patients' AR. OBJECTIVE(S): To evaluate the impact of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585337/ https://www.ncbi.nlm.nih.gov/pubmed/37869069 http://dx.doi.org/10.1016/j.rcsop.2023.100340 |
_version_ | 1785122933412200448 |
---|---|
author | House, Rachel Kritikos, Vicky Cvetkovski, Biljana Rimmer, Janet Yan, Kwok Cheong, Lynn Bousquet, Jean Lourenco, Olga Bosnic-Anticevich, Sinthia |
author_facet | House, Rachel Kritikos, Vicky Cvetkovski, Biljana Rimmer, Janet Yan, Kwok Cheong, Lynn Bousquet, Jean Lourenco, Olga Bosnic-Anticevich, Sinthia |
author_sort | House, Rachel |
collection | PubMed |
description | BACKGROUND: The Allergic Rhinitis Clinical Management Pathway (AR-CMaP) was developed to overcome the challenge of implementing current AR guidelines in the Australian community pharmacy practice and support pharmacists in optimally managing patients' AR. OBJECTIVE(S): To evaluate the impact of AR-CMaP on patients' behaviour and pharmacists' needs in managing AR in the pharmacy. METHODS: This study used a cross-sectional, pre-post study design in which the primary outcome was the appropriateness of medications purchased from community pharmacies in Australia. Patient data were collected before and after the implementation of AR-CMaP. Pharmacist needs were recorded before and after AR-CMaP training. Data were analysed descriptively. RESULTS: Six pharmacies, 19 pharmacists and a total of 416 patients were included in the study; 206 pre-AR-CMaP implementation and 210 post-AR-CMaP implementation. Pre-AR-CMaP, 22.4% of patients purchased appropriate AR medication compared with 29.0% post-AR-CMaP implementation. Over half the patient cohort (52%) consulted a pharmacist pre-AR-CMaP and 37% consulted a pharmacist post-AR-CMaP implementation. Post-AR-CMaP, pharmacists reported increased awareness of barriers such as patients' lack of time, patients' perceptions about the pharmacist's role and patient choice to self-manage. Pharmacists also rated an increased desire to interact with other health care providers (HCPs) in caring for patients with AR. CONCLUSIONS: While there was a non-statistically significant increase in the proportion of patients purchasing optimal AR medication, AR-CMaP did empower patients to self-select their own medication without further detriment. Moreover, following the implementation of AR-CMaP, pharmacists developed a greater awareness of their role in AR management, exemplified by their increased desire to be actively involved in AR management and increased interaction with other HCPs. Future research needs to explore more effective tools to support pharmacists' clinical decision-making and target patients' self-selection of AR medications. This study highlights that there is an ingrained self-reliance of AR decision-making that has become a habit for people living with AR. |
format | Online Article Text |
id | pubmed-10585337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105853372023-10-20 The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy House, Rachel Kritikos, Vicky Cvetkovski, Biljana Rimmer, Janet Yan, Kwok Cheong, Lynn Bousquet, Jean Lourenco, Olga Bosnic-Anticevich, Sinthia Explor Res Clin Soc Pharm Article BACKGROUND: The Allergic Rhinitis Clinical Management Pathway (AR-CMaP) was developed to overcome the challenge of implementing current AR guidelines in the Australian community pharmacy practice and support pharmacists in optimally managing patients' AR. OBJECTIVE(S): To evaluate the impact of AR-CMaP on patients' behaviour and pharmacists' needs in managing AR in the pharmacy. METHODS: This study used a cross-sectional, pre-post study design in which the primary outcome was the appropriateness of medications purchased from community pharmacies in Australia. Patient data were collected before and after the implementation of AR-CMaP. Pharmacist needs were recorded before and after AR-CMaP training. Data were analysed descriptively. RESULTS: Six pharmacies, 19 pharmacists and a total of 416 patients were included in the study; 206 pre-AR-CMaP implementation and 210 post-AR-CMaP implementation. Pre-AR-CMaP, 22.4% of patients purchased appropriate AR medication compared with 29.0% post-AR-CMaP implementation. Over half the patient cohort (52%) consulted a pharmacist pre-AR-CMaP and 37% consulted a pharmacist post-AR-CMaP implementation. Post-AR-CMaP, pharmacists reported increased awareness of barriers such as patients' lack of time, patients' perceptions about the pharmacist's role and patient choice to self-manage. Pharmacists also rated an increased desire to interact with other health care providers (HCPs) in caring for patients with AR. CONCLUSIONS: While there was a non-statistically significant increase in the proportion of patients purchasing optimal AR medication, AR-CMaP did empower patients to self-select their own medication without further detriment. Moreover, following the implementation of AR-CMaP, pharmacists developed a greater awareness of their role in AR management, exemplified by their increased desire to be actively involved in AR management and increased interaction with other HCPs. Future research needs to explore more effective tools to support pharmacists' clinical decision-making and target patients' self-selection of AR medications. This study highlights that there is an ingrained self-reliance of AR decision-making that has become a habit for people living with AR. Elsevier 2023-10-05 /pmc/articles/PMC10585337/ /pubmed/37869069 http://dx.doi.org/10.1016/j.rcsop.2023.100340 Text en Crown Copyright © 2023 Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article House, Rachel Kritikos, Vicky Cvetkovski, Biljana Rimmer, Janet Yan, Kwok Cheong, Lynn Bousquet, Jean Lourenco, Olga Bosnic-Anticevich, Sinthia The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy |
title | The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy |
title_full | The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy |
title_fullStr | The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy |
title_full_unstemmed | The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy |
title_short | The impact of implementing an allergic rhinitis clinical management pathway (AR-CMaP) in the community pharmacy |
title_sort | impact of implementing an allergic rhinitis clinical management pathway (ar-cmap) in the community pharmacy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585337/ https://www.ncbi.nlm.nih.gov/pubmed/37869069 http://dx.doi.org/10.1016/j.rcsop.2023.100340 |
work_keys_str_mv | AT houserachel theimpactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT kritikosvicky theimpactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT cvetkovskibiljana theimpactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT rimmerjanet theimpactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT yankwok theimpactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT cheonglynn theimpactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT bousquetjean theimpactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT lourencoolga theimpactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT bosnicanticevichsinthia theimpactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT houserachel impactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT kritikosvicky impactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT cvetkovskibiljana impactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT rimmerjanet impactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT yankwok impactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT cheonglynn impactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT bousquetjean impactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT lourencoolga impactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy AT bosnicanticevichsinthia impactofimplementinganallergicrhinitisclinicalmanagementpathwayarcmapinthecommunitypharmacy |